China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a Phase III clinical study for its anti-IL-17A monoclonal antibody (mAb) in the treatment of moderate to severe plaque psoriasis. The study, which was approved in China in February 2020, marks a significant step forward in the development of this potential new treatment option.
Dual Targeting of IL-17A and IL-17F Dimers
The drug under study can simultaneously target homologous dimers IL-17A-A and IL-17F-F, as well as heterodimers IL-17A-F. These dimers act on receptors IL-17RA and IL-17RC and are known to promote the expression of other pro-inflammatory cytokines such as IL-6, TNF α, IL-1 β, IL-20 family cytokines, GM-CSF, and effector proteins. This leads to the activation of neutrophils, macrophages, epithelial cells, and fibroblasts, playing a crucial role in the pathophysiology of many autoimmune diseases, including psoriasis.
Market Competition and Regulatory Landscape
In the China market, Novartis’ Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab), both IL-17A products, have already been approved. Additionally, eight similar products from domestic firms have entered clinical development. Suncadia Bio’s vunakizumab and Zhixiang Jintai Bi’s xeligekimab are awaiting regulatory decisions. Globally, only UCB’s Bimzelx, an IL-17A/F-targeted therapy, is commercially available and has filed for marketing in China in April this year.-Fineline Info & Tech
